Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Non-Current Assets: 2019-2024

Historic Non-Current Assets for Pharming Group N.V (PHAR) over the last 6 years, with Dec 2024 value amounting to $121.5 million.

  • Pharming Group N.V's Non-Current Assets rose 36.88% to $196.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $196.2 million, marking a year-over-year increase of 36.88%. This contributed to the annual value of $121.5 million for FY2024, which is 17.04% down from last year.
  • Per Pharming Group N.V's latest filing, its Non-Current Assets stood at $121.5 million for FY2024, which was down 17.04% from $146.5 million recorded in FY2023.
  • Pharming Group N.V's Non-Current Assets' 5-year high stood at $155.2 million during FY2020, with a 5-year trough of $121.5 million in FY2024.
  • In the last 3 years, Pharming Group N.V's Non-Current Assets had a median value of $146.5 million in 2023 and averaged $138.8 million.
  • As far as peak fluctuations go, Pharming Group N.V's Non-Current Assets increased by 13.75% in 2020, and later dropped by 17.04% in 2024.
  • Over the past 5 years, Pharming Group N.V's Non-Current Assets (Yearly) stood at $155.2 million in 2020, then decreased by 4.75% to $147.9 million in 2021, then grew by 0.29% to $148.3 million in 2022, then fell by 1.20% to $146.5 million in 2023, then dropped by 17.04% to $121.5 million in 2024.